NASDAQ · EYPTHealthcareLab Analytical Instruments

EyePoint financials

$3.42+3.32%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Dec 31
FY24
Dec 31
FY23
Dec 31
FY22
Dec 31
FY21
Dec 31
FY20
Dec 31
FY19
Dec 31
FY18
Dec 31
Revenue$31.4M$43.3M$46.0M$41.4M$36.9M$34.4M$20.4M$4.6M
Gross profit$29.3M$39.6M$41.4M$33.1M$28.8M$28.6M$17.7M$4.6M
Gross margin93.4%91.4%89.9%79.9%77.9%83.1%86.8%100.0%
Operating income-$243.4M-$145.9M-$75.1M-$99.6M-$55.3M-$37.3M-$47.9M-$39.0M
Net income-$232.0M-$130.9M-$70.8M-$102.3M-$58.4M-$45.4M-$56.8M-$86.1M
Net margin−739.4%−302.4%−153.8%−247.0%−158.1%−131.8%−278.9%−1884.2%
Diluted EPS$-3.17$-2.32$-1.82$-2.74$-2.03$-3.54$-5.44$-12.70
EBITDA-$241.1M-$144.3M-$74.6M-$76.5M-$52.5M-$34.6M-$45.3M-$39.0M
Operating cash flow-$240.1M-$126.2M$1.9M-$65.0M-$50.1M-$14.4M-$56.7M—
Free cash flow-$243.4M-$130.3M-$1.6M-$67.2M-$50.3M-$14.8M-$56.9M—
Diluted shares73.3M56.3M38.9M37.3M28.8M12.8M10.4M6.8M

Balance sheet

Period endDec 31Dec 31Dec 31Dec 31Dec 31Dec 31
Cash & equivalents$101.8M$99.7M$281.3M$95.6M$178.6M$44.9M
Short-term investments$204.3M$271.2M$49.8M$48.9M$33.0M$0.00
Total debt$0.00$0.00$0.00$39.8M$36.6M$38.0M
Total assets$364.0M$418.5M$355.2M$180.4M$263.4M$91.7M
Total liabilities$57.9M$82.0M$88.9M$84.0M$79.0M$73.2M
Shareholders' equity$306.1M$336.5M$266.3M$96.4M$184.4M$18.5M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology